



Healthcare | Small Cap
Vaidya Sane Ayurved Laboratories Ltd demonstrates very strong financial health, primarily driven by exceptional profitability, rapid growth, and an almost debt-free status. The company excels at turning its investments into high profits and is expanding its revenues, earnings, and assets at an outstanding rate. This low-risk, high-growth profile is a significant strength. However, there are areas of concern. The company's ability to generate cash from its core operations is weak, and its immediate cash reserves are low, creating a reliance on collecting payments quickly. Furthermore, while the company invests heavily in new assets for growth, the efficiency of this new capital in generating sales is declining. Shareholder returns are currently minimal, as profits are being reinvested into the business instead of being paid out as dividends. The future outlook is positive, supported by a strong, profitable, and debt-free foundation, but depends on improving operational cash flow and asset efficiency.
Vaidya Sane Ayurved Laboratories Ltd demonstrates very strong financial health, primarily driven by exceptional profitability, rapid growth, and an almost debt-free status. The company excels at turning its investments into high profits and is expanding its revenues, earnings, and assets at an outstanding rate. This low-risk, high-growth profile is a significant strength. However, there are areas of concern. The company's ability to generate cash from its core operations is weak, and its immediate cash reserves are low, creating a reliance on collecting payments quickly. Furthermore, while the company invests heavily in new assets for growth, the efficiency of this new capital in generating sales is declining. Shareholder returns are currently minimal, as profits are being reinvested into the business instead of being paid out as dividends. The future outlook is positive, supported by a strong, profitable, and debt-free foundation, but depends on improving operational cash flow and asset efficiency.
Overall Valuation Score
Markets Depth NSE
Buy Orders
Bid
Quantity
Orders
No buy depth
Total
0
0
Sell Orders
Ask
Quantity
Orders
No sell depth
Total
0
0
Markets Today NSE
High
0.00
Low
0.00
Open
0.00
Close
0.00
Prev Close
0.00
Avg Price
0.00
Volume
0
Last Traded Quantity
0
Last Traded Time
N/A
Price Movement Indicator
Today's Low: 0.00
Today's High: 0.00
P/E RATIO (TTM)
42.96
Industry Median
50.32
Small Cap Median
47.21
P/E RATIO
23.57
P/B RATIO
2.42
Industry Median
4.64
Small Cap Median
3.74
P/S RATIO
1.98
Industry Median
3.81
Small Cap Median
2.17
Others
PEG RATIO
1.09
EV/EBITDA RATIO
11.90
The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹201.5 as on Jul 16, 2026.
The company is in a phase of exceptional and broad-based growth. It is expanding its sales, operating profit, and net income at an outstanding rate, indicating strong market acceptance and a successful business strategy. This top-line and bottom-line momentum is matched by a rapid expansion of its asset base, reflecting significant reinvestment for the future. The earnings available to each shareholder are also growing impressively. There are no weaknesses in this category; the company's growth profile is a clear and powerful strength.
| Growth Ratios | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|
| Revenue Growth Rate | 0 | -9.09 | 18.89 |
| Operating Profit Growth Rate | -44.44 | 160 | 15.38 |
| Earnings Per Share (EPS) Growth | -59.04 | 261.7 | 25.74 |
| Asset Growth Rate | 27.27 | 10 | 36.36 |
| Net Income Growth Rate | -60 | 250 | 28.57 |
Revenue Growth Rate
Operating Profit Growth Rate
Earnings Per Share (EPS) Growth
Asset Growth Rate
Net Income Growth Rate
Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.
| NO | Company Name | Health Score | P/E Ratio | Valuation | OPM | EPS | Latest Profit & Loss |
|---|---|---|---|---|---|---|---|
| 1 | Vaidya Sane Ayurved Laboratories Ltd | 7.72 | 23.57 | Undervalued | 15.00 | 4.69 | 9.00 |
| 2 | Maitreya Medicare Ltd | 7.34 | -33.01 | Neutral | -0.46 | -1.96 | -2.47 |
| 3 | Lotus Eye Hospital & Institute Ltd | 6.07 | 328.53 | Overvalued | 3.38 | 0.04 | 0.08 |
| 4 | Nephro Care India Ltd | 5.69 | 43.87 | Neutral | 8.32 | 2.04 | 3.37 |
0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 1 Hour Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Analyzing moving average trends and crossovers. Green/Red badges indicate if the current condition passes or fails.
Comparing stock price performance (normalized) against benchmark indices over time.
Recent daily trading volume represented as a bar chart, alongside historical averages.
Current closing price relative to the 52-week highest and lowest prices.
No Stock Reports Available at This Moment.
Vaidya Sane Ayurved Laboratories Ltd, operating as Madhavbaug, is a leading Indian healthcare company specializing in Ayurvedic treatment for chronic diseases like cardiac conditions and diabetes. It integrates modern diagnostics with traditional Ayurveda, offering clinics, hospitals, and wellness centers across India, alongside a range of Ayurvedic products and lifestyle management programs.
P/E Ratio (TTM): Price to Earnings ratio shows how much an investor pays for every rupee of the company's earnings. Vaidya Sane Ayurved Laboratories Ltd's P/E ratio (TTM) is 42.96, compared to the industry median of 50.32 and large cap median of 47.21.
P/B Ratio: Price to Book ratio compares a company's market price to its book value per share. Vaidya Sane Ayurved Laboratories Ltd's P/B ratio is 2.42, compared to the industry median of 4.64 and large cap median of 3.74.
P/S Ratio: Price to Sales ratio compares a company's market value to its total revenue. Vaidya Sane Ayurved Laboratories Ltd's P/S ratio is 1.98, compared to the industry median of 3.81 and large cap median of 2.17.
PEG Ratio: PEG ratio adjusts the P/E ratio for expected earnings growth. Vaidya Sane Ayurved Laboratories Ltd's PEG ratio is 1.09.
EV/EBITDA Ratio: This ratio compares a company's enterprise value to its earnings before interest, tax, depreciation, and amortization. Vaidya Sane Ayurved Laboratories Ltd's EV/EBITDA ratio is 11.90.
Return on Equity (ROE): ROE measures how much profit a company generates from shareholders' invested capital. Vaidya Sane Ayurved Laboratories Ltd's ROE is 10.23%.
Return on Assets (ROA): ROA measures how efficiently a company converts its assets into net profit. Vaidya Sane Ayurved Laboratories Ltd's ROA is 14.29%.
Return on Capital Employed (ROCE): ROCE measures how efficiently a company generates profit from all the capital it employs. Vaidya Sane Ayurved Laboratories Ltd's ROCE is 15%.
Operating Margin: Operating margin shows what percentage of revenue remains after covering operating expenses. Vaidya Sane Ayurved Laboratories Ltd's operating margin is 14.02%.
Net Margin: Net margin shows what percentage of revenue converts into final net profit. Vaidya Sane Ayurved Laboratories Ltd's net margin is 8.41%.
Current Ratio: The current ratio measures a company's ability to pay short-term liabilities using short-term assets. Vaidya Sane Ayurved Laboratories Ltd's current ratio is 2.
Debt to Equity Ratio: This ratio shows the proportion of debt a company uses relative to shareholders' equity. Vaidya Sane Ayurved Laboratories Ltd's debt-to-equity ratio is 0.03.
Interest Coverage Ratio: This ratio shows how easily a company can pay interest on its outstanding debt from its operating earnings. Vaidya Sane Ayurved Laboratories Ltd's interest coverage ratio is 12.
Dividend Per Share (DPS): DPS shows the total dividend paid per share in the latest financial year. Vaidya Sane Ayurved Laboratories Ltd's DPS is ₹0.
Earnings Per Share (EPS): EPS shows how much profit is allocated to each outstanding share. Vaidya Sane Ayurved Laboratories Ltd's EPS is 25.74.
(Source line: "Ratios as of 22 Nov 2026, based on last traded price of ₹201.50. Data sourced from BSE/NSE Exchange Filings & Public Terminal Data.")
Founded: 1999
Headquarters: Thane, Maharashtra
Core Offerings: Ayurvedic Clinics & Hospitals, Ayurvedic Medicines & Products, Cardiac Care Programs, Diabetes Management Programs
Stock Listing: NSE (MADHAVBAUG), BSE ({bse})
Promoter: Dr. Rohit Madhav Sane
Founded in 1999 by Dr. Rohit Sane with a vision to provide evidence-based Ayurvedic treatment. Pioneered an integrated approach combining modern diagnostics with traditional Ayurvedic principles. Expanded its clinic network significantly across India. Developed specialized treatments for cardiac diseases and diabetes. Launched an IPO and listed on NSE Emerge in 2022, later migrating to the NSE Main Board in 2023. Continuously focuses on research and product development in Ayurvedic medicine.
| Segment Name | Revenue % | EBITDA |
|---|---|---|
| Ayurvedic Healthcare Services & Products | 100% | Operating Profit |
Ayurvedic Healthcare Services & Products: Operates a chain of over 250 Madhavbaug clinics and hospitals across India, offering non-invasive cardiac care, diabetes management, and other chronic disease treatments.
Provides specialized Ayurvedic medicines, dietary supplements, and lifestyle modification programs developed through extensive research.
Focuses on a blend of traditional Ayurvedic principles with modern diagnostic tools and evidence-based treatment protocols.
Dr. Rohit Madhav Sane: Chairman, Managing Director & CEO. A visionary physician, he founded Madhavbaug in 1999, pioneering an integrated approach to chronic disease management using Ayurveda.
No major subsidiaries reported.
IPO in 2022; Stock split (face value Rs. 10 to Rs. 5) effective September 2022; Migration from NSE Emerge to NSE Main Board in September 2023.
The Vaidya Sane Ayurved Laboratories Ltd share price today is ₹201.50 on NSE (MADHAVBAUG), as of 22 Nov 2026.
As of 22 Nov 2026, Vaidya Sane Ayurved Laboratories Ltd share price is ₹201.50, with previous close ₹201.50. Today's range is ₹201.50 to ₹201.50. The 52-week range is ₹130.05 to ₹294.
As of today, Vaidya Sane Ayurved Laboratories Ltd's market cap is ₹211.58 crore (Small Cap).
Vaidya Sane Ayurved Laboratories Ltd's current P/E ratio is 42.96, compared to the DIVERSIFIED CONSUMER SERVICES sector average of 39.50.
Vaidya Sane Ayurved Laboratories Ltd's current P/B ratio is 2.42.
Vaidya Sane Ayurved Laboratories Ltd's current dividend yield is N/A. Last dividend of ₹0.00 per share was declared on N/A.
Vaidya Sane Ayurved Laboratories Ltd's EPS (TTM) is ₹25.74.
Vaidya Sane Ayurved Laboratories Ltd, operating as Madhavbaug, is a leading Indian healthcare company specializing in Ayurvedic treatment for chronic diseases like cardiac conditions and diabetes. It integrates modern diagnostics with traditional Ayurveda, offering clinics, hospitals, and wellness centers across India, alongside a range of Ayurvedic products and lifestyle management programs.
Vaidya Sane Ayurved Laboratories Ltd is promoted by Dr. Rohit Madhav Sane, holding 66.34% as of 22 Nov 2026.
Vaidya Sane Ayurved Laboratories Ltd is listed on NSE (MADHAVBAUG) and BSE ({bse}). Its next quarterly results are expected on August 2024 (for Q1 FY25).